Consequently, the development of kidney-specific antisense oligonucleotide (ASO) or adeno-associated viral (AAV) transduction methods is advantageous, as these approaches can selectively inhibit ANGPTL4 in proximal tubules, glomerular podocytes, and glomerular endothelial cells, thereby avoiding the adverse systemic effects associated with whole-body ANGPTL4 loss (Srivastava et al., 2024)
Clinical Evidence on GLP-1 and Oral Contraceptive Interaction Direct clinical trials specifically measuring birth control efficacy during GLP-1 therapy remain sparse
The present analysis showed that injection site had a small effect on the bioavailability of semaglutide, which was lower following injection in the thigh compared to abdominal injection
It is commonly prescribed for both type 2 diabetes and obesity
Unethical skin bleaching with glutathione, August 2016 Recommended Products Was this Article helpful
FLOW is the first dedicated kidney outcome trial to demonstrate that a GLP1-RA has a clear benefit on kidney in patients with type 2 diabetes and CKD